logo
Analysts Offer Insights on Energy Companies: Chord Energy (CHRD), PBF Energy (PBF) and Delek US Holdings (DK)

Analysts Offer Insights on Energy Companies: Chord Energy (CHRD), PBF Energy (PBF) and Delek US Holdings (DK)

Globe and Mail5 days ago
Companies in the Energy sector have received a lot of coverage today as analysts weigh in on Chord Energy (CHRD – Research Report), PBF Energy (PBF – Research Report) and Delek US Holdings (DK – Research Report).
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chord Energy (CHRD)
Wells Fargo analyst Hanwen Chang maintained a Buy rating on Chord Energy yesterday and set a price target of $143.00. The company's shares closed last Monday at $106.72, close to its 52-week low of $99.40.
According to TipRanks.com, Chang is a 1-star analyst with an average return of -1.1% and a 45.6% success rate. Chang covers the NA sector, focusing on stocks such as Crescent Energy Company Class A, Magnolia Oil & Gas, and Matador Resources. ;'>
Currently, the analyst consensus on Chord Energy is a Strong Buy with an average price target of $129.40, implying a 19.0% upside from current levels. In a report issued on June 30, RBC Capital also maintained a Buy rating on the stock with a $145.00 price target.
PBF Energy (PBF)
In a report released yesterday, Roger Read from Wells Fargo maintained a Hold rating on PBF Energy, with a price target of $24.00. The company's shares closed last Monday at $26.97.
According to TipRanks.com, Read is a 3-star analyst with an average return of 0.9% and a 54.4% success rate. Read covers the NA sector, focusing on stocks such as Calumet Specialty Products, Liberty Oilfield Services, and HF Sinclair Corporation. ;'>
PBF Energy has an analyst consensus of Moderate Sell, with a price target consensus of $20.00, a -28.6% downside from current levels. In a report issued on July 8, Morgan Stanley also maintained a Hold rating on the stock with a $20.00 price target.
Delek US Holdings (DK)
Bank of America Securities analyst Jean Ann Salisbury maintained a Sell rating on Delek US Holdings yesterday and set a price target of $13.00. The company's shares closed last Monday at $26.20.
According to TipRanks.com, Salisbury is a 4-star analyst with an average return of 9.2% and a 65.2% success rate. Salisbury covers the NA sector, focusing on stocks such as Venture Global, Inc. Class A, Enterprise Products Partners, and Cheniere Energy Partners. ;'>
The word on The Street in general, suggests a Hold analyst consensus rating for Delek US Holdings with a $18.00 average price target, a -32.0% downside from current levels. In a report issued on July 10, Morgan Stanley also maintained a Sell rating on the stock with a $15.00 price target.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Class Action Lawsuit Filed: Fortrea Holdings Inc. (FTRE) - Join by August 1, 2025 - Contact Levi & Korsinsky
Class Action Lawsuit Filed: Fortrea Holdings Inc. (FTRE) - Join by August 1, 2025 - Contact Levi & Korsinsky

Globe and Mail

time23 minutes ago

  • Globe and Mail

Class Action Lawsuit Filed: Fortrea Holdings Inc. (FTRE) - Join by August 1, 2025 - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - July 21, 2025) - If you suffered a loss on your Fortrea Holdings Inc. (NASDAQ: FTRE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: or contact Joseph E. Levi, Esq. via email at jlevi@ or call (212) 363-7500 to speak to our team of experienced shareholder advocates. Cannot view this video? Visit: THE LAWSUIT: A class action securities lawsuit was filed against Fortrea Holdings Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fortrea overestimated the amount of revenue the long-term projects in its portfolio, the Pre-Spin Projects, were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the transition services agreements; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company's post-spin-off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Fortrea Holdings Inc. stock during the relevant time frame - even if you still hold your shares - go to to learn about your rights to seek a recovery. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

Globe and Mail

time23 minutes ago

  • Globe and Mail

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. Halper Sadeh encourages iTeos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@ or zhalper@ The investigation concerns whether iTeos and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for iTeos shareholders; (2) determine whether Concentra is underpaying for iTeos; and (3) disclose all material information necessary for iTeos shareholders to adequately assess and value the merger consideration. On behalf of iTeos shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store